Search results
Showing 16 to 30 of 30 results for ranibizumab
Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.
Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)
Evidence-based recommendations on bevacizumab gamma (Lytenava) for treating wet age-related macular degeneration in adults.
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.
Evidence-based recommendations on faricimab (Vabysmo) for treating visual impairment caused by macular oedema after retinal vein occlusion in adults.
further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular...
further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema...
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]
Awaiting development Reference number: GID-TA11065 Expected publication date: TBC
This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema following retinal vein occlusion in adults.
Limited macular translocation for wet age-related macular degeneration (IPG339)
Evidence-based recommendations on limited macular translocation for wet age related macular degeneration. This involves cutting and moving the macula on an a nearby healthier area of the retina.
View recommendations for IPG339Show all sections
Evidence-based recommendations on idebenone (Raxone) for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over.
Show all sections
inconvenience, risk of adverse events and – especially when aflibercept or ranibizumab is used – substantial costs. People typically...
Past technology appraisal appeals and decisions
Ranibizumab for the treatment of diabetic macular oedema (TA237)
This guidance has been updated and replaced by NICE technology appraisal guidance 274.
Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)
NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .